Differences in Type 1 and Type 2 intracytoplasmic cytokines, detected by flow cytometry, according to immunosuppression (cyclosporine A vs. tacrolimus) in stable renal allograft recipients

Clinical Transplantation

Volumn 13, Issue 5, 1999, Pages 400-409

  Rostaing, Lionel ^a   Puyoo, Olivier ^a   Tkaczuk, Jean ^a   Peres, Christine ^a   Rouzaud, Anne ^a   Cisterne, Jean Marc ^a   De Preval, Claude ^a   Ohayon, Elie ^a   Durand, Dominique ^a   Abbal, Michel ^a  

^a NONE

Author keywords

Cyclosporine A; Cytokine flow cytometry; Interferon ; Interleukin 2; Kidney transplantation; Tacrolimus; Th1 Th2 cytokines

Indexed keywords

CD4 ANTIGEN; CD8 ANTIGEN; CYCLOSPORIN A; CYTOKINE; GAMMA INTERFERON; IMMUNOSUPPRESSIVE AGENT; INTERLEUKIN 10; INTERLEUKIN 2; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 6; IONOMYCIN; MONENSIN; PHORBOL 13 ACETATE 12 MYRISTATE; TACROLIMUS;

ADULT; ARTICLE; CELL STIMULATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOKINE PRODUCTION; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; MALE; MONONUCLEAR CELL; PRIORITY JOURNAL; T LYMPHOCYTE; T LYMPHOCYTE SUBPOPULATION;

ADULT; CELLS, CULTURED; CYCLOSPORINE; CYTOKINES; FEMALE; FLOW CYTOMETRY; HUMANS; IMMUNOSUPPRESSIVE AGENTS; INTERFERON TYPE II; INTERLEUKIN-2; KIDNEY TRANSPLANTATION; MALE; MIDDLE AGED; T-LYMPHOCYTE SUBSETS; TACROLIMUS; TH1 CELLS; TH2 CELLS;

EID: 0032823696     PISSN: 09020063     EISSN: None     Source Type: Journal    
DOI: 10.1034/j.1399-0012.1999.130506.x     Document Type: Article

References (39)

1. MOSSMAN TR, CHERWINSKI H, BOND MW, Giedlin MA, COFFMAN RL. Two types of murine helper clone: I: definition according to profiles of lymphokine activities and secreted proteins. J Immunol 1986: 136: 2348.
2. DEL PRETE GF, DE CARLI M, MASTROMAURO C, BIAGIOTTI R, MACCHIA D, FALAGIANI P, RICCI M, ROMAGNANI S. Purified protein derivative of Mycobacterium tuberculosis and excretory secretory-antigens of Toxocara canis expand in vitro human T cells with stable and opposite (Type 1 T helper or Type 2 T helper) profile of cytoline production. J Clin Invest 1991: 88: 346.
3. CARTER LL, DUTTON RW. Type 1 and Type 2: a fundamental dichotomy for all T-cell subsets. Curr Opin Immunol 1996: 8: 336.
4. PICCOTTI JR, CHAN SY, VANBUSKIRK, AM, EICHWALD EJ, BISHOP DK. Are Th2 helper T lymphocytes beneficial, deleterious, or irrelevant in promoting allograft survival? Transplantation 1997: 63: 619.
5. NICKERSON P, STEURER W, STEIGER J, ZHENG X, STEELE AW, STROM TB. Cytokines and the Th1/Th2 paradigm in transplantation. Curr Opin Immunol 1994: 6: 757.
6. STARZL TE, FUNG JJ, JORDAN ML et al. Kidney transplantation under FK506. JAMA 1990: 264: 63.
7. MATTILA PS. The action of cyclosporin a and FK506 on T-lymphocyte activation. Biochem Soc Transact 1996: 24: 45.
8. HUTCHINSON IV. The mode of action of Prograf® (Tacrolimus) and its significance for long-term graft survival. New Horiz Kidney Transplant 1997: 1: 22.
9. JORDAN ML, KARACHI R, SHAPIRO R, SMITH D, VIVAS CA, SCANTLEBURY VP, GRITSCH HA, MCCAULEY J, RANDHAWA P, DEMETRIS AJ, MCMICHAEL J, FUNG JJ, STARZL TE. Tacrolimus rescue therapy for renal allograft rejection: five-year experience. Transplantation 1997: 63: 223.
10. MORRISSEY PE, GOHH R, SHAFFER D, CROSSON A, MADRAS PN, SAHYOUN AI, MONACO AP. Correlation of clinical outcomes after tacrolimus conversion for resistant kidney rejection or cyclosporine toxicity with pathologic staging by the Banff criteria. Transplantation 1997: 63: 845.
11. SHER LS, COSENZA CA, MICHEL J et al. Efficacy of tacrolimus as rescue therapy for chronic rejection in orthotopic liver transplantation. Transplantation 1997: 64: 258.
12. MAYER AD, DMITREWSKI J, SQUIFFLET JP et al. Multicenter randomized trial comparing tacrolimus (FK506) and cyclosporine in the prevention of renal allograft rejection. Transplantation 1997: 64: 436.
13. PIRSCH JD, MILLER J, DEIERHOI MH, VICENTI F, FILO RS. A comparison of tacrolimus (FK506) and cyclosporine for immunosuppression after cadaveric renal transplantation. Transplantation 1997: 63: 977.
14. GJERSTSON DW, CECKA JM, TERASAKI PI. The relative effects of FK506 and cyclosporin on short- and long-term kidney graft survival. Transplantation 1995: 60: 1384.
15. ANDERSON SJ, COLECLOUGH C. Regulation of CD4 and CD8 expression on mouse T cells: active removal from the surface by two mechanisms. J Immunol 1993: 151: 5123.
16. lck, increased association with clathrin-coated pits, and altered endosomal sorting. J Exp Med 1993: 178: 1209.
17. MERVILLE P, POUTEIL-NOBLE C, WIJDENES J, POTAUX L, TOURAINE JL, BANCHEREAU J. Detection of single cells secreting IFN-gamma, 11-6, and IL-10 in irreversibly rejected human kidney allografts and their modulation by II-2 and IL-4. Transplantation 1993: 55: 639.
18. ANDERSSON U, ANDERSSON J, LINDFORS A, WAGNER K, MOLLER G, HEUSSER CH. Simultaneous production of interleukin-2, interleukin-4 and interferon-γ by activated human blood lymphocytes. Ent J Immunol 1990: 20: 1591.
19. POWERS GD, ABBAS AK, MILLER RA. Frequencies of IL-2 and IL-4 secreting T cells in naive and antigen stimulated lymphocyte populations. J Immunol 1988: 140: 3352.
20. BUCY RP, PANOSKALTSIS-MORTARI A, HUANG GQ, LI M, KARR L, Ross M, RUSSEL JH, MURPHY KM, WEAVER CT. Heterogeneity of single cell cytokine gene expression in clonalT cell populations. J Exp Med 1994: 180: 1829.
21. JUNG T, SHAUER U, HEUSSER C, NEUMSANN C, RIEGER C. Detection of intracellular cytokines by flow cytometry. J Immunol Methods 1993: 159: 197.
22. PICKER LJ, SINGH MK, ZDRAVESKI Z, TREER JR, WALDROP SL, BERGSTRESSER PR, MAINO VC. Direct demonstration of cytokine synthesis heterogeneity among human memory/effector T cells by flow cytometry. Blood 1995: 86: 1408.
23. + T cells from normal and immunodeficient donors using directly conjugated anti-cytokine antibodies and three colour flow cytometry. Clin Exp Immunol 1996: 105:517.
24. PETERSEN CM, Christensen EI, ANDRESEN BS, MOLLER BK. Internalization, lysosomal degradation and new synthesis of surface membrane CD4 in phorbol ester-activated T-lymphocytes and U-937 cells. Exp Cell Res 1992: 201: 160.
25. LANG T, KRAMS SM, MARTINEZ OM. Production of IL-4 and IL-10 does not lead to immune quiescence in vascularized human organ grafts. Transplantation 1996: 62: 776.
26. MARTINEZ OM, VILLANUEVA JC, LAKE J, ROBERTS JP, ASCHER NL, KRAMS SM. IL-2 and IL-5 gene expression in response to alloantigen in liver allograft recipients and in vitro. Transplantation 1993: 55: 1159.
27. NORONHA IL, EBERLEIN-GONSKA M, HARTLEY B, STEPHENS S, CAMERON JS, WALDHERR R. In situ expression of tumor necrosis factor-alpha, interferon-gamma, and interleukin-2 receptors in renal allograft biopsies. Transplantation 1992: 54: 1017.
28. KIRK AD, IBRAHIM MA, BOLLINGER RR, DAWSON DV, FINN OJ. Renal allograft infiltrating lymphocytes: a prospective analysis of in vitro growth characteristics and clinical relevance. Transplantation 1992: 53: 329.
29. WU CJ, KURBEGOV D, LATTIN B, BURCHARD E, FINKLE C, VALANTINE H, BILLINGHAM ME, STARNES VA, CLAYBERGER C. Cytokine gene expression in human cardiac allograft recipients. Transplant Immunol 1994: 2: 199.
30. MOREL D, NORMAND E, LEMOINE C, MERLIO JP, VELOURS J, ASTIER T, BONNET F, APARICIO M, POTAUX L, BLOCH B. Tumor necrosis factor alpha in human kidney transplant rejection. Analysis by in situ hybridization. Transplantation 1993: 55: 773.
31. DESCAMPS-LATSCHA B. The immune system in end-stage renal disease. Curr Opin Nephrol Hypertens 1993: 2: 883.
32. MÜLLER TF, GREBE SO, NEUMANN C, HEYMANNS J, RADSAK K, SPRENGER H, LANGE H. Persistent long-term changes in lymphocyte subsets induced by polyclonal antibodies. Transplantation 1997: 64: 1432.
33. VAN DEN BERG AP, TWILHAAR WN, MESANDER G, VAN SON WJ, VAN DER BIJ W, KLOMPMAKER IJ, SLOFF JH, HAUW THE T, DE LEIJ LHFM. Quantification of immunosuppression by flow cytometric measurement of the capacity of T cells for interleukin-2 production. Transplantation 1998: 65: 1066.
34. ANDERSSON J, NAGY S, GROTH CG, ANDERSSON U. FK506 and cyclosporine inhibit antigen or mitogen-induced monokine and lymphokine production in vitro. Transplant Proc 1992: 24: 321.
35. HAN CW, IMAMURA M, HASHINO S et al. Differential effects of the immunosuppressants cyclosporin A. FK506 and KM 2210 on cytokine gene expression. Bone Marrow Transplant 1995: 15: 733.
36. WANG SC, ZEEVI A, JORDAN ML, SIMMONS RL, TWEARDY DJ. FK506, rapamycin, and cyclosporin: effects on IL-4 and IL-10 mRNA levels in a T-helper 2 cell line. Transplant Proc 1991: 23: 2920.
37. ANDERSSON J, NAGY S, GROTH CG, ANDERSSON U. The effects of FK506 on cytokine production are dependent on the mode of cell activation. Transplant Proc 1991: 23: 2916.
38. MURAYAMA K, SAWAMURA M, MURAKAMI H, TAMURA J, NARUSE T, TSUCHIYA J. FK506 and cyclosporin A enhance IL-6 production in monocytes: a single cell assay. Mediators Inflamm 1994: 3: 375.
39. LEMSTER B, WOO J, THOMSON AW. Blood lymphocytes of autoimmune disease patients receiving FK506 exhibit normal ex vivo cytokine gene expression and proliferative responses. Immunol Lett 1993: 38: 179.